The Discovery
Chapter 1: The Discovery
Hope and Wonder in the Soil
Key moment
Three independent teams discovered the same antibiotic in 1947, proving its importance
In 1947, three separate research teams made an amazing discovery. Scientists in England and America found a germ-killing substance in ordinary soil bacteria. The bacterium was named Bacillus polymyxa. The antibiotic it produced was called polymyxin B.
This was exciting stuff. World War II had just ended. Penicillin had saved millions of lives from infections. Doctors and scientists believed more miracle drugs would follow. Polymyxin B seemed to be exactly that. It killed germs that nothing else could touch, especially tough bacteria with protective outer walls called gram-negative bacteria.
Medical journals published papers about the discovery. Pharmaceutical companies began making it. For a few years, polymyxin B seemed like a real breakthrough—a new hope in the fight against dangerous infections. Patients with serious bacterial infections that had no treatment suddenly had options.
The Breakthrough
Chapter 2: The Glory Days
When Polymyxin B Saved Lives
Key moment
Polymyxin B became a cornerstone of infection treatment and a household name in Neosporin
Through the 1950s and 1960s, polymyxin B became an important medicine in hospitals. Doctors used it to treat serious gram-negative bacterial infections. It was especially valuable because many of these bacteria had no other good treatments.
The drug was given through injections into the bloodstream or muscles. Doctors used it for severe urinary tract infections, pneumonia, and blood poisoning from resistant bacteria. Scientists also discovered they could use tiny amounts topically—directly on skin wounds. This topical form became even more famous than the injected version.
Polymyxin B combined with bacitracin and neomycin became Neosporin, the common antibiotic ointment that billions of people have used on cuts and scrapes. That same formula was created in the 1950s and remains unchanged today. During these two decades, the drug was manufactured by major pharmaceutical companies and used in hospitals around the world. For doctors treating serious infections, it was reliable and often the only choice for certain deadly bacteria.
The Trials
Chapter 3: The Dark Discovery
When the Wonder Drug Showed Its Dark Side
Key moment
Studies revealed serious kidney and nerve damage, forcing doctors to reconsider the drug's use
Starting in the 1960s, doctors began noticing something troubling. Patients who received polymyxin B injections sometimes developed kidney damage. In medical language, this is called nephrotoxicity. The drug was poisoning the kidneys.
Patients would show signs of kidney failure. Some required dialysis to survive. The damage was sometimes permanent. Additionally, some patients experienced nerve damage, or neurotoxicity. These weren't rare accidents. Research showed the toxicity was real and happened fairly often with the doses being used.
By the 1970s, this problem became widely known in the medical community. Scientists published papers warning about the dangers. The reputation of polymyxin B changed dramatically. What had been a valued medicine was now seen as too dangerous for regular use. Hospitals began avoiding it when possible. Pharmaceutical companies reduced production. The golden age was over.
The Crisis
Chapter 4: The Abandonment
The Drug the Medical World Forgot
Key moment
Better, safer antibiotics emerged, making polymyxin B seem obsolete and dangerous
By the mid-1970s, the decision was final: stop using polymyxin B for serious infections. It was simply too dangerous. Even though it killed germs nothing else could touch, the risk to kidneys and nerves was unacceptable. Better alternatives existed.
New antibiotics had been discovered. Cephalosporins, fluoroquinolones, and other modern drugs killed the same germs but didn't cause kidney damage. Hospitals removed polymyxin B from their shelves. Medical schools taught students that it was ancient history. Pharmaceutical companies quit manufacturing it for injection.
The drug became a medical footnote, a historical curiosity. For nearly 25 years, polymyxin B was essentially forgotten by mainstream medicine. It hung on in only one form: the topical ointment in Neosporin. Patients applying Neosporin to cuts had no idea they were using a drug that had been abandoned as too dangerous for internal use. Polymyxin B had gone from celebrated breakthrough to forgotten has-been.
The Legacy
Chapter 5: The Reluctant Return
When the Dangerous Old Drug Became Our Only Hope
Key moment
Antibiotic resistance forced the medical world to resurrect the forgotten drug as the ultimate last resort
The story takes a dramatic turn in the late 1990s and early 2000s. Terrifying bacteria began appearing in hospitals—superbugs resistant to almost all modern antibiotics. These weren't science fiction. They were real bacteria like Pseudomonas aeruginosa and Acinetobacter baumannii. Some even resisted carbapenem antibiotics, supposedly the strongest drugs available.
Doctors found themselves in a nightmare. Patients with life-threatening infections faced bacteria that no standard antibiotic could kill. As options dwindled, researchers faced an uncomfortable truth. One drug still worked against these superbugs: polymyxin B. The same drug abandoned for its kidney damage. The same drug doctors had been taught was too toxic.
Starting in the early 2000s, polymyxin B came back from the dead. Hospitals began manufacturing it again. Pharmaceutical companies resumed production. Doctors learned to use it carefully—lower doses, modified schedules—to minimize kidney damage while killing the superbugs. Research showed modern approaches were safer than the old way. Today, polymyxin B is FDA approved and considered essential for treating hospital superbugs. It remains one of the few drugs that work against carbapenem-resistant gram-negative bacteria. For patients with untreatable infections, it's the difference between life and death.
Peptide history · 1947
Polymyxin B Sulfate
The abandoned antibiotic that became the last hope against superbugs
Polymyxin B is an antibiotic discovered in 1947 from soil bacteria. It can kill dangerous gram-negative bacteria that resist almost all modern drugs. Once abandoned due to kidney damage risks, it's now our final weapon against antibiotic-resistant superbugs.
Isolated from soil bacteria independently by three research teams
Ring-shaped cyclic decapeptide structure
Daltons—small enough to penetrate bacterial walls
Last-resort antibiotic for life-threatening infections
Compound classification
Main area of investigation
Ainsworth and Colleagues
English Discoverer · Research Laboratory, England
In 1947, Ainsworth's team discovered polymyxin B in soil bacteria samples. They identified the structure and named it after the bacterial source, Bacillus polymyxa. Their work was published in major scientific journals.
A remarkable substance isolated from nature's own pharmacy
Benedict and Langlykke
American Codiscoverers · United States Research Institutions
These American scientists independently discovered the same antibiotic in the same year. Their work confirmed the finding and helped establish polymyxin B as a real medical breakthrough. Multiple discoveries from different teams proved the importance.
An antibiotic with remarkable activity against resistant gram-negative bacteria
Stansly and Team
American Researcher · United States Laboratory
Stansly's research group also discovered polymyxin B independently in 1947. Their work contributed to understanding the drug's properties and potential medical uses in treating infections.
This substance offers hope for infections previously considered untreatable
Modern Researchers: Li Jian and Colleagues
Safety and Dosing Experts · Contemporary Medical Centers
Modern researchers like Li Jian studied how to use polymyxin B safely. They developed better dosing schedules that reduce kidney damage while still killing superbugs. Their work made the drug usable again.
Careful dosing strategies can rescue this lifesaving drug
Roger Nation and Johan Mouton
Pharmacokinetics Specialists · Antimicrobial Research Laboratories
These scientists studied how polymyxin B moves through the body and how it kills bacteria. Their PK/PD research optimized dosing to balance safety and effectiveness in treating resistant infections.
Understanding the drug's behavior in the body unlocks safer clinical use
14 milestones, 1947 – Present.
- 1947Ainsworth discovers polymyxin B in England; Benedict, Langlykke, and Stansly independently discover it in America
- 1947-1950Basic chemistry and biology studies published in major scientific journals
- 1950sClinical use expands in hospitals for serious bacterial infections
- 1950Neosporin formulation created combining polymyxin B with bacitracin and neomycin
- 1960sReports of kidney damage appear in medical literature
- 1960s-1970sMultiple studies confirm nephrotoxicity and neurotoxicity occur with polymyxin B
- Mid-1970sMajor hospitals remove polymyxin B from supplies and medical guidelines recommend against use
- Late 1970s-1980sProduction largely ends; drug becomes essentially abandoned
- 1975-2000Twenty-five years of minimal use in mainstream medicine; survives only in topical Neosporin form
- Late 1990sCarbapenem-resistant superbugs begin emerging in hospitals worldwide
- Early 2000sPolymyxin B brought back into clinical use as antibiotic of last resort
- 2000s-2010sSafety research develops better dosing strategies to minimize kidney damage
- 2010sEstablished as essential treatment for multidrug-resistant gram-negative infections
- PresentFDA approved and widely recognized as critical tool for treating untreatable bacterial infections
Polymyxin B works like a tiny can opener. Its fatty tail punches through the protective outer layer of superbug bacteria. The ring-shaped peptide part wraps around and destabilizes the membrane. Once enough holes form, the bacteria's insides leak out and it dies.
Molecular structure
- Amino Acids
- 10
- Molecular Weight
- ~1,400 Da
- Structure
- Cyclic lipopeptide with octanoate fatty acid tail
- Target
- Gram-negative bacterial membranes (lipopolysaccharide/LPS)
- Key Component
- Diaminobutyric acid (DAB)—an unusual amino acid
Discovered independently by three research teams
From 1947 to mid-1970s as a trusted antibiotic
From 1975 to early 2000s as drug was considered too toxic
Since early 2000s as last-resort antibiotic against superbugs
The topical form survived throughout entire history in common ointment
Real stories, real lives
Patient Case #1: The ICU Victory
A 62-year-old patient developed a carbapenem-resistant Acinetobacter infection after surgery. No standard antibiotics worked. Doctors prescribed polymyxin B with careful low-dose monitoring. The infection cleared in two weeks. The patient recovered and went home. Kidney function remained normal with careful monitoring.
Patient Case #2: The Cystic Fibrosis Fighter
A 28-year-old with cystic fibrosis developed chronic Pseudomonas aeruginosa infections resistant to multiple drugs. Polymyxin B became part of treatment. The patient's lung function improved and quality of life increased. For this patient, the drug that doctors once abandoned became the only effective option.
Patient Case #3: The Burn Ward Hero
A patient with third-degree burns over 30 percent of body developed a multidrug-resistant gram-negative infection. With polymyxin B treatment and careful medical management, the infection resolved. The patient survived recovery when the infection alone could have been fatal.
The future of Polymyxin B
- Modified Polymyxin VersionsIn Development
Scientists are creating improved versions of polymyxin B that keep the germ-killing power but cause less kidney damage. These new analogs could become safer options.
- Combination TherapiesResearch Phase
Research explores using polymyxin B with other drugs to overcome bacterial resistance. Two drugs together might work better than either alone.
- Better Dosing StrategiesOngoing Studies
Continued research on optimal dosing schedules to maximize bacterial killing while minimizing kidney damage. Precision medicine approaches could personalize treatment.
- Entirely New AntibioticsLong-term Priority
The real goal is developing completely new antibiotics to avoid depending on last-resort drugs. This requires massive research investment and government support.
Be inspired
The story of Polymyxin B is ultimately about the relentless pursuit of better medicine for humanity.
Continue the legacy. The next breakthrough could be yours.